CoMentis, Inc. is headquartered in South San Francisco, with research operations in both South San Francisco and Oklahoma City. The company is engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.
The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.
CoMentis currently has three product development programs in its pipeline: ATG-3, a topical (eye drop) anti-angiogenesis compound for neovascular AMD in Phase II development; CTS-21166, an orally active beta-secretase inhibitor for Alzheimer’s disease in Phase I development; and GTS-21, an oral agonist of the α7 nACh receptor for ADHD in Phase II development, and a series of next generation agonists of the α7 nACh receptor in preclinical development.